140 related articles for article (PubMed ID: 36495784)
1. Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer.
Huh KY; Lim Y; Yoon DY; Hwang JG; Sim S; Kang J; Wang J; Kim M; Jang SB; Shreeve SM; Mehta J; Haddish-Berhane N; Oh J; Lee S; Yu KS
Lung Cancer; 2023 Jan; 175():112-120. PubMed ID: 36495784
[TBL] [Abstract][Full Text] [Related]
2. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
Ahn MJ; Han JY; Lee KH; Kim SW; Kim DW; Lee YG; Cho EK; Kim JH; Lee GW; Lee JS; Min YJ; Kim JS; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Kim HT; Lee DH; Kim S; Cho BC
Lancet Oncol; 2019 Dec; 20(12):1681-1690. PubMed ID: 31587882
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment-naive patients with advanced EGFR mutation-positive non-small cell lung cancer: Protocol of an open-label, single-arm phase II trial.
Lee B; Ji W; Lee JC; Song SY; Shin YS; Cho YH; Park JE; Park H; Choi CM
Thorac Cancer; 2023 Aug; 14(22):2233-2237. PubMed ID: 37365915
[TBL] [Abstract][Full Text] [Related]
4. Lazertinib Versus Gefitinib as First-Line Treatment in Patients With
Cho BC; Ahn MJ; Kang JH; Soo RA; Reungwetwattana T; Yang JC; Cicin I; Kim DW; Wu YL; Lu S; Lee KH; Pang YK; Zimina A; Fong CH; Poddubskaya E; Sezer A; How SH; Danchaivijitr P; Kim Y; Lim Y; An T; Lee H; Byun HM; Zaric B
J Clin Oncol; 2023 Sep; 41(26):4208-4217. PubMed ID: 37379502
[TBL] [Abstract][Full Text] [Related]
5. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
Cho BC; Han JY; Kim SW; Lee KH; Cho EK; Lee YG; Kim DW; Kim JH; Lee GW; Lee JS; Shim BY; Kim JS; Chun SH; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Lee Y; Lee DH; Kang JA; Lee N; Kwon MJ; Espenschied C; Yablonovitch A; Ahn MJ
J Thorac Oncol; 2022 Apr; 17(4):558-567. PubMed ID: 34958928
[TBL] [Abstract][Full Text] [Related]
6. Effects of Acid-Reducing Agents on the Pharmacokinetics of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
Kim B; Lee J; Jang H; Lee N; Mehta J; Jang SB
Adv Ther; 2022 Oct; 39(10):4757-4771. PubMed ID: 35962934
[TBL] [Abstract][Full Text] [Related]
7. Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
Reungwetwattana T; Cho BC; Lee KH; Pang YK; Fong CH; Kang JH; Lee YG; Lim CS; Danchaivijitr P; Lim YN; Lee Y; How SH; Geater S; Lee SS; Min YJ; Kim JH; Lee JS; Lee GW; Soo RA; Lee SY; Choi S; Ahn MJ
J Thorac Oncol; 2023 Oct; 18(10):1351-1361. PubMed ID: 37702629
[TBL] [Abstract][Full Text] [Related]
8. Lazertinib: First Approval.
Dhillon S
Drugs; 2021 Jun; 81(9):1107-1113. PubMed ID: 34028784
[TBL] [Abstract][Full Text] [Related]
9. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
Cho BC; Felip E; Hayashi H; Thomas M; Lu S; Besse B; Sun T; Martinez M; Sethi SN; Shreeve SM; Spira AI
Future Oncol; 2022 Feb; 18(6):639-647. PubMed ID: 34911336
[TBL] [Abstract][Full Text] [Related]
10. A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).
Choi J; Lee JE; Choi CM; Oh IJ; Lee KY; Jang TW; Lee SH; Kim EY; Park DW; Park SH; Lee SY
Thorac Cancer; 2022 Dec; 13(23):3431-3435. PubMed ID: 36259253
[TBL] [Abstract][Full Text] [Related]
11. A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11).
Kim KH; Yoon S; Ahn HK; Lee SY; Lee GW; Lee SS; Cho JH; Cho BC; Yoon HI; Lim SM
Clin Lung Cancer; 2022 Dec; 23(8):e536-e539. PubMed ID: 36002368
[TBL] [Abstract][Full Text] [Related]
12. Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
Soo RA; Cho BC; Kim JH; Ahn MJ; Lee KH; Zimina A; Orlov S; Bondarenko I; Lee YG; Lim YN; Lee SS; Lee KH; Pang YK; Fong CH; Kang JH; Lim CS; Danchaivijitr P; Kilickap S; Yang JC; Arslan C; Lee H; Park SN; Cicin I
J Thorac Oncol; 2023 Dec; 18(12):1756-1766. PubMed ID: 37865896
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.
Nishio M; Murakami H; Ohe Y; Hida T; Sakai H; Kasahara K; Imamura F; Baba T; Kubota K; Hosomi Y; Shimokawa T; Hayashi H; Miyadera K; Tamura T
Invest New Drugs; 2019 Dec; 37(6):1207-1217. PubMed ID: 30790152
[TBL] [Abstract][Full Text] [Related]
14. ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naïve Japanese patients with EGFR mutation-positive non-small-cell lung cancer.
Azuma K; Nishio M; Hayashi H; Kiura K; Satouchi M; Sugawara S; Hida T; Iwamoto Y; Inoue A; Takeda K; Ikeda S; Nakagawa T; Takeda K; Asahina S; Komatsu K; Morita S; Fukuoka M; Nakagawa K
Cancer Sci; 2018 Aug; 109(8):2532-2538. PubMed ID: 29807396
[TBL] [Abstract][Full Text] [Related]
15. Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Wu YL; Saijo N; Thongprasert S; Yang JC; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang JJ; Mok TS; Young H; Haddad V; Rukazenkov Y; Fukuoka M
Lung Cancer; 2017 Feb; 104():119-125. PubMed ID: 28212993
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Calvo E; Lee JS; Kim SW; Moreno V; deCastro Carpeno J; Weilert D; Laus G; Mann H; Vishwanathan K
J Clin Pharmacol; 2019 Aug; 59(8):1099-1109. PubMed ID: 30875094
[TBL] [Abstract][Full Text] [Related]
17. Lazertinib: on the Way to Its Throne.
Lee J; Hong MH; Cho BC
Yonsei Med J; 2022 Sep; 63(9):799-805. PubMed ID: 36031779
[TBL] [Abstract][Full Text] [Related]
18. The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects.
Cao B; Ma T; Zhang Y; Huang L; Lin H; Jiang H; Zhao Y; Geng Y; Yang Y; Cao S; Li J
Invest New Drugs; 2024 Jun; 42(3):289-298. PubMed ID: 38602625
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
[TBL] [Abstract][Full Text] [Related]
20. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
